secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2024-08-27T23:59:59+00:00
Accession:  0001493152-24-034019
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharmaceuticals launches generic methotrexate sodium 2.5 mg tablets
-------------------------------------------------------------------------

- Product launched for ALL, mycosis fungoides, non-Hodgkin's lymphoma, rheumatoid arthritis, severe psoriasis, pJIA.
- Total US market for methotrexate sodium 2.5 mg tablets was ~$63M (12 months ended May 2024, IQVIA).
- Marketed under Elite Laboratories, Inc. label; DEA/cGMP facility in Northvale, NJ.
- Elite (OTCQB: ELTP) develops and manufactures niche generic products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224034019/0001493152-24-034019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224034019/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-034019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer